Document
As filed with the Securities and Exchange Commission on January 24, 2018
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1 REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933 MENLO THERAPEUTICS INC.
(Exact name of registrant as specified in its charter) |
| | |
Delaware | 2834 | 45-3757789 |
(State or other jurisdiction of
incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer
Identification Number) |
200 Cardinal Way, 2nd Floor
Redwood City, California 94063
(650) 486-1416
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Steven L. Basta
President and Chief Executive Officer
Menlo Therapeutics Inc.
200 Cardinal Way, 2nd Floor
Redwood City, California 94063
(650) 486-1416
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
|
| |
Stephen B. Thau Alfredo B. D. Silva Shannon E. Sibold Morrison & Foerster LLP
755 Page Mill Road Palo Alto, California 94034
Telephone: (650) 813-5600 Facsimile: (650) 494-0792 | Alan C. Mendelson Mark V. Roeder Brian J. Cuneo Latham & Watkins LLP 140 Scott Drive Menlo Park, California 94025 Telephone: (650) 328-4600 Facsimile: (650) 463-2600 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-222324)
If this Form is a post effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
| | | | |
Large accelerated filer | ☐ | | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | (do not check if a smaller reporting company) | Smaller reporting company | ☐ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
_________________________________
CALCULATION OF REGISTRATION FEE
|
| | | | |
Title of Each Class of
Securities to be Registered | Amount to be Registered (1) | Proposed Maximum Offering Price Per Share | Proposed Maximum Aggregate Offering Price (2) | Amount of Registration Fee (2) |
Common Stock, par value $0.0001 per share | 575,000 | $17.00 | $9,775,000 | $1,216.99 |
| |
(1) | Represents only the additional number of shares being registered and includes 75,000 additional shares of common stock that the underwriters have the option to purchase. This does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1, as amended (File No. 333-222324) (“Prior Registration Statement”). |
| |
(2) | The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, or the Securities Act, based on the proposed maximum aggregate offering price. The Registrant previously registered securities with an aggregate offering price not to exceed $127,075,000 on the Prior Registration Statement, which was declared effective by the Securities and Exchange Commission on January 24, 2018. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $9,775,000 are hereby registered, which includes shares subject to the underwriters’ option to purchase additional shares. |
_____________________
This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933,
as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the sole purpose of increasing the aggregate number of shares of common stock offered by the Registrant by 575,000 shares. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference in this filing.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
|
| | |
Exhibit
No. | | Description |
5.1 | | |
| | |
23.1 | | |
| | |
23.2 | | |
| | |
24.1 | | |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on January 24, 2018.
|
| |
MENLO THERAPEUTICS INC. |
| |
By: | Steven Basta |
| President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated below:
|
| | | | |
Name | | Capacity | | Date |
| | |
/s/ Steven Basta | | President, Chief Executive Officer, and Director (Principal Executive Officer) | | January 24, 2018 |
Steven Basta | | |
| | |
/s/ Kristine Ball | | Senior Vice President, Corporate Strategy and Chief Financial Officer (Principal Financial Officer) | | January 24, 2018 |
Kristine Ball | | |
| | |
* | | Director | | January 24, 2018 |
Paul Berns | | |
| | |
* | | Director | | January 24, 2018 |
Albert Cha | | |
| | |
* | | Director | | January 24, 2018 |
Ted Ebel | | |
| | |
* | | Director | | January 24, 2018 |
David McGirr | | |
| | |
* | | Director | | January 24, 2018 |
Aaron Royston | | |
| | |
* | | Director | | January 24, 2018 |
Scott Whitcup | | |
|
| |
*By | /s/ Steven Basta |
| Steven Basta |
| As Attorney-In-Fact |